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Center, Stanford, CABackground: Chronic graft-versus-host disease (cGVHD)
remains a major barrier to successful use of HCT. The
incidence, clinical presentation, course, and outcomes of
GVHD-related syndromes are not well described in a
multi-center setting.
Methods: The Chronic GVHD Consortium enrolled allogeneic
HCT recipients in a prospective, longitudinal, observational
study, and followed them closely for development of four
GVHD-related syndromes: Late acute GVHD, cGVHD (both
deﬁned according to NIH consensus criteria), bronchiolitis
obliterans syndrome (BOS), and cutaneous sclerosis (CS).
Participants were enrolled up to 121 days after HCTas long as
they had not already developed a late immune-mediated
disorder. Research samples were drawn at day 100 and
again at day 180 or 365 post HCT. Subjects who developed
GVHD syndromes underwent additional sampling and data
collection.
Results: AllogeneicHCTrecipients (N¼913)wereenrolledat13
centers from March 2011 to May 2014. The cumulative inci-
dence of cGVHD was 51% with a median onset of 7.3 months
(Table), and86%ofcGVHDcaseswerediagnosedwithin theﬁrst
year after HCT. Late acute GVHD and BOS had particularly poor
survival with 29% and 36% non-relapse mortality (NRM) at 2
years after syndrome onset. In multivariable analysis, KPS <
80% at HCT (HR: 2.6, 95% CI:1.6-4.0, p<0.001) was associated
with a higher risk of late acute GVHD. Unrelated cord bloodTable
Syndrome Number
of cases
Cumulative incidence
at 2 years (95% CI)
Medi
mos
Late acute GVHD 85 11% (9%-14%) 5.2
Chronic GVHD 339 51% (47%-55%) 7.3
BOS 25 5% (3%-8%) 11.4
CS 44 10% (7%-13%) 13.5transplantation (UCBT) was associated with a lower risk of
cGVHD (HR 0.5, 95% CI 0.3-0.7, p<0.001). At 2 years after HCT
the probability of GVHD-free, relapse-free survival was 21%
(95% CI: 17%-24%) including only the late immune-mediated
disorders, and 9% (95% CI: 7%-12%) if classic acute GVHD was
included as an event.
Conclusions: This is the ﬁrst prospective study evaluating
incidence and outcomes of GVHD-related syndromes. The
onset of the syndromes varied from a median of 5.2 to 13.5
months after HCT, indicating need for continuous close
monitoring and management. Amongst the GVHD-related
syndromes, late acute GVHD and BOS have particularly
poor overall survival, indicating a need for more
effective treatments. Since research samples were banked,
further studies examining biologic correlates of these
syndromes are planned. Investigators interested in access
to data or samples should contact the Chronic GVHD
Consortium. (http://www.rarediseasesnetwork.org/cgvhd/
about/ OR chronicgvhdstudies@fhcrc.org).
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Background: Allo-LS is an important complication of HCT.
Early RV infection is assumed to be a predictor for allo-LS.
We routinely screen patients pre-HCT for RV, both in
Nasopharyngeal Aspirate (NPA) and BAL. This study
evaluates the impact of RV RNA-DNA-positivity pre-HCT
from NPA or BAL respectively on the occurrence of allo-LS.
Methods: We prospectively included all consecutive pedi-
atric HCT recipients from January 2007eOctober 2013. A PCR
on a panel of RV (Adenovirus, Coronavirus, Rhinovirus, RSV,
Bocavirus, Inﬂuenzavirus A and B, Parainﬂuenza 1-3 and 2-4,
human-Metapneumovirus) was performed on BAL and NPA
samples a week prior to HCT. Primary endpoint was allo-LS,
deﬁned according to international criteria as Idiopathic
Pneumonia Syndrome (acute respiratory symptoms,
pulmonary inﬁltrates, absence of infection) or Bronchiolitis
Obliterans (HRCT changes such as air trapping and ground
glass, abnormal obstructive pulmonary function test,
absence of infection). Cox proportional hazard models were
used for analyses.an time to onset,
(range)
NRM 2 years after
onset (95% CI)
Survival 2 years
after onset (95% CI)
(3.2-15.6) 29% (15%-54%) 57% (33%-76%)
(1.8-22.0) 17% (11%-26%) 77% (67%-84%)
(2.8-21.7) 36% (15%-90%) 62% (22%-86%)
(4.0-26.5) 12% (4%-36%) 88% (65%-96%)
